Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGXT | P21549 | 3/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 6/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 5/20 | 0.36 |
| ▸ | BRS3 | P32247 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10175527 | 0.82 | ATM (0.43) | AGXTMGLLALOX5GRM2PRMT6 | |
| SCHEMBL8643271 | 0.80 | LMNA (0.47) | FFAR2NOTUM | |
| SCHEMBL10224808 | 0.77 | GRM2 (0.42) | AGXTMGLLALOX5GRM2PRMT6 | |
| SCHEMBL10309756 | 0.77 | GRM2 (0.39) | AGXTMGLLALOX5GRM2NR1H2 | |
| SCHEMBL4507051 | 0.75 | AGXT (0.65) | AGXTMGLLALOX5PRMT6 | |
| SCHEMBL23844438 | 0.75 | L3MBTL3 (0.46) | AGXTMGLLALOX5PRMT6NOTUM | |
| SCHEMBL29157655 | 0.74 | NOTUM (0.45) | NOTUM | |
| SCHEMBL29157654 | 0.74 | NOTUM (0.45) | NOTUM | |
| SCHEMBL24681614 | 0.72 | NOTUM (0.41) | FFAR2NOTUM | |
| SCHEMBL24681245 | 0.72 | NOTUM (0.41) | FFAR2NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178743-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178743-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | ADORA1, HRH4, P2RY10 | AGXT 2011/4885MGLL 4175/4885ALOX5 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.